Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 127

Results For "ICU"

1369 News Found

Syngene revenue from operations up 17 per cent in Q2FY22
News | October 21, 2021

Syngene revenue from operations up 17 per cent in Q2FY22

The quarter also saw continued investment in new technologies and the successful implementation of several digitization and automation projects across operations


We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare
interviews | October 20, 2021

We plan to expand into Chennai, Hyderabad and Vijayawada: Rajinish Menon, Founder & CEO, Sukino Healthcare

Continuum care is a concept that’s gaining acceptance in South India and Sukino Healthcare with its presence in Bangalore and Kochi has made rapid strides catering to this need. It now plans to expand to many more cities in the region. Indian Pharma Post caught up with Rajinish Menon, Founder & CEO, Sukino Healthcare who gave us an insight into the company’s operations.


FDA approves Cyltezo, the first interchangeable biosimilar to Humira
Drug Approval | October 20, 2021

FDA approves Cyltezo, the first interchangeable biosimilar to Humira

Second interchangeable biosimilar product approved by agency


MSN Labs launches drug for diabetes management
Drug Approval | October 19, 2021

MSN Labs launches drug for diabetes management

The company claims that its Empagliflozin tablets are the most affordable in India


Imfinzi plus tremelimumab significantly improved overall survival in liver cancer
Biotech | October 18, 2021

Imfinzi plus tremelimumab significantly improved overall survival in liver cancer

The trial met the primary endpoint of overall survival with a single priming dose of tremelimumab plus Imfinzi every four weeks vs. sorafenib


U.S. FDA advisory committee recommends J&J booster dose
Biotech | October 18, 2021

U.S. FDA advisory committee recommends J&J booster dose

U.S. FDA to decide whether to authorize a booster dose in the coming days


Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline
Biotech | October 18, 2021

Ipsen enters exclusive worldwide tie-up with Accent for its pre-clinical R&D oncology pipeline

Ipsen obtains an exclusive license to develop, manufacture and commercialize a pre-clinical stage METTL3-inhibitor programme


Exelixis in-licenses second anti-cancer compound from Aurigene
Biotech | October 15, 2021

Exelixis in-licenses second anti-cancer compound from Aurigene

U.S. FDA has accepted the investigational new drug application for phase 1 clinical trial in non-Hodgkin’s lymphoma


Govt launches `One Health’ surveillance programme
Public Health | October 15, 2021

Govt launches `One Health’ surveillance programme

The consortium envisages carrying out surveillance of important bacterial, viral and parasitic infections of zoonotic as well as transboundary pathogens


Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients
Biotech | October 13, 2021

Roche’s 8-year safety data of Ocrevus shows reduced risk in multiple sclerosis patients

New safety data show a consistent benefit-risk profile across all Ocrevus clinical trials